Company Profile: Labcorp Holdings Inc. (LH)
LH insider trades (13 months) →$353.92 −0.47% vs. previous close · Market cap $28.74B
Today's multi-factor rank: 227 of 461 · see the ranking
Market and Valuation
Price & Market
52-Week Range
Volume
Valuation Multiples
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 30, 2026. The P/E is the price divided by that EPS.
Dividends
Valuation Context
P/E vs sector (indicative)
Loading historical OHLCV database...
Financial Statements TTM (Trailing 12 Months)
Income Statement
Margins
Per Share
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 30, 2026. The P/E is the price divided by that EPS.
Balance Sheet & Liquidity
Cash Flows
Profitability
Historical Evolution (Last 4 Years)
Income Statement
Balance Sheet
Cash Flow
EPS and Earnings Per Share
Key EPS Metrics
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 30, 2026. The P/E is the price divided by that EPS.
Growth and Margins
Per Share
Cash Flows (TTM)
EPS Surprise History - Last 4 Quarters
Actual vs. Analyst Estimates · Green = beat expectations · Red = missed
| Quarter | Period | Actual EPS | Estimated EPS | Difference | Surprise % | Currency |
|---|
Ownership Structure
Ownership Distribution
Shares & Short Interest
Governance Score (1=Best, 10=Worst)
Top Institutional Holders
Position Change: ▲ Increased · ▼ Reduced · = Unchanged
| Organization | Report Date | % Shares | No. Shares | Value (USD) | Change % |
|---|
Top Mutual Funds
Position Change: ▲ Increased ▼ Decreased = Unchanged
| Fund | Report Date | % Shares | No. Shares | Value (USD) | Change % |
|---|
Recent Insider Trades
| Executive / Insider | Title | Date | Action | Shares |
|---|
Options Chain
CALLS
| Strike | Last | Bid | Ask | Vol. | O.I. | IV |
|---|
PUTS
| Strike | Last | Bid | Ask | Vol. | O.I. | IV |
|---|
Labcorp Holdings Inc. (LH) SEC filings: 10-K, 10-Q and 8-K
Direct links to financial reports filed with the SEC.
| Type | Date | Official link |
|---|---|---|
| 8-K | 2026-10-28 | View filing ↗ |
| 8-K | 2026-10-21 | View filing ↗ |
| 8-K | 2026-09-30 | View filing ↗ |
| 8-K | 2026-09-22 | View filing ↗ |
| 8-K | 2026-09-10 | View filing ↗ |
| 8-K | 2026-08-28 | View filing ↗ |
| 8-K | 2026-08-17 | View filing ↗ |
| 8-K | 2026-08-14 | View filing ↗ |
| 10-Q | 2026-08-05 | View filing ↗ |
| 8-K | 2026-07-30 | View filing ↗ |
Company and Executive Profile
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
General Information
Key Executives
| Name | Title | Age | Total pay |
|---|---|---|---|
| Mr. Adam H. Schechter | President, CEO & Chairman | 60 | 4.18M |
| Ms. Julia A. Wang | Executive VP & CFO | 54 | 1.68M |
| Dr. Brian J. Caveney J.D., M.D., M.P.H. | Exec VP, President of Biopharma Laboratory Services & Chief Medical and Scientific Officer | 51 | 1.49M |
| Mr. Jonathan C. Meltzer Ph.D. | Executive VP & COO | - | - |
| Mr. Peter J. Wilkinson | Senior VP & Chief Accounting Officer | 54 | - |
| Mr. Akinbolade Oyegunwa M.B.A., Ph.D. | Executive VP and Chief Information & Technology Officer | 42 | - |
| Mr. Dewey Steadman C.F.A. | Senior Vice President of Investor Relations | - | - |
| Ms. Kathryn Wright Kyle | Executive VP, Chief Legal Officer & Corporate Secretary | 54 | - |
You have seen the engine room
A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.